Takaji Wakita

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4167900/publications.pdf Version: 2024-02-01



Τλκλιι \λ/λκιτλ

#	Article	IF	CITATIONS
1	Galectin-9 restricts hepatitis B virus replication via p62/SQSTM1-mediated selective autophagy of viral core proteins. Nature Communications, 2022, 13, 531.	5.8	31
2	The kinesin KIF4 mediates HBV/HDV entry through the regulation of surface NTCP localization and can be targeted by RXR agonists in vitro. PLoS Pathogens, 2022, 18, e1009983.	2.1	5
3	Novel Neplanocin A Derivatives as Selective Inhibitors of Hepatitis B Virus with a Unique Mechanism of Action. Antimicrobial Agents and Chemotherapy, 2022, 66, .	1.4	2
4	SEB genotyping: SmartAmp-Eprimer binary code genotyping for complex, highly variable targets applied to HBV. BMC Infectious Diseases, 2022, 22, .	1.3	0
5	Occludinâ€binding singleâ€chain variable fragment and antigenâ€binding fragment antibodies prevent hepatitis C virus infection. FEBS Letters, 2021, 595, 220-229.	1.3	2
6	Identification of Two Critical Neutralizing Epitopes in the Receptor Binding Domain of Hepatitis B Virus preS1. Journal of Virology, 2021, 95, .	1.5	8
7	Dual Agonist of Farnesoid X Receptor and Takeda G Proteinâ€Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo. Hepatology, 2021, 74, 83-98.	3.6	22
8	Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations. Journal of Virology, 2021, 95, e0240120.	1.5	3
9	MafF Is an Antiviral Host Factor That Suppresses Transcription from Hepatitis B Virus Core Promoter. Journal of Virology, 2021, 95, e0076721.	1.5	11
10	NTCP Oligomerization Occurs Downstream of the NTCP-EGFR Interaction during Hepatitis B Virus Internalization. Journal of Virology, 2021, 95, e0093821.	1.5	11
11	Development of an intervention system for linkage-to-care and follow-up for hepatitis B and C virus carriers. Hepatology International, 2021, , 1.	1.9	2
12	Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay. Journal of Gastroenterology, 2020, 55, 441-452.	2.3	7
13	Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus. Hepatology Research, 2020, 50, 1128-1140.	1.8	6
14	Establishment of a novel hepatitis B virus culture system using immortalized human hepatocytes. Scientific Reports, 2020, 10, 21718.	1.6	9
15	Engineering Cellular Biosensors with Customizable Antiviral Responses Targeting Hepatitis B Virus. IScience, 2020, 23, 100867.	1.9	14
16	Establishment of infectious genotype 4 cell culture-derived hepatitis C virus. Journal of General Virology, 2020, 101, 188-197.	1.3	5
17	Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly. Virus Research, 2019, 271, 197677.	1.1	16
18	Activation of protein kinase R by hepatitis C virus RNA-dependent RNA polymerase. Virology, 2019, 529, 226-233.	1.1	12

#	Article	IF	CITATIONS
19	Bardoxolone methyl as a novel potent antiviral agent against hepatitis B and C viruses in human hepatocyte cell culture systems Antiviral Research, 2019, 169, 104537.	1.9	13
20	An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes. PLoS ONE, 2019, 14, e0216139.	1.1	19
21	Human-rat chimeric anti-occludin monoclonal antibodies inhibit hepatitis C virus infection. Biochemical and Biophysical Research Communications, 2019, 514, 785-790.	1.0	5
22	Concept of Viral Inhibitors via NTCP. Seminars in Liver Disease, 2019, 39, 078-085.	1.8	22
23	Screening for inhibitor of episomal DNA identified dicumarol as a hepatitis B virus inhibitor. PLoS ONE, 2019, 14, e0212233.	1.1	8
24	Cell Culture Systems of HCV Using JFH-1 and Other Strains. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a036806.	2.9	10
25	Cell and Animal Models for Studying Hepatitis B Virus Infection and Drug Development. Gastroenterology, 2019, 156, 338-354.	0.6	76
26	A Single Adaptive Mutation in Sodium Taurocholate Cotransporting Polypeptide Induced by Hepadnaviruses Determines Virus Species Specificity. Journal of Virology, 2019, 93, .	1.5	26
27	Peroxiredoxin 1, a Novel HBx-Interacting Protein, Interacts with Exosome Component 5 and Negatively Regulates Hepatitis B Virus (HBV) Propagation through Degradation of HBV RNA. Journal of Virology, 2019, 93, .	1.5	30
28	Acidic polysaccharides isolated from marine algae inhibit the early step of viral infection. International Journal of Biological Macromolecules, 2019, 124, 282-290.	3.6	27
29	Establishment of Replication-Competent HCV Strain with Minimum Modifications. Methods in Molecular Biology, 2019, 1911, 73-83.	0.4	1
30	Novel stable HBV producing cell line systems for expression and screening antiviral inhibitor of hepatitis B virus in human hepatoma cell line. Biochemical and Biophysical Research Communications, 2018, 498, 64-71.	1.0	1
31	Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model. Journal of Virology, 2018, 92, .	1.5	27
32	Chemical array system, a platform to identify novel hepatitis B virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide. Scientific Reports, 2018, 8, 2769.	1.6	17
33	The aryl hydrocarbon receptor–cytochrome P450 1A1 pathway controls lipid accumulation and enhances the permissiveness for hepatitis C virus assembly. Journal of Biological Chemistry, 2018, 293, 19559-19571.	1.6	42
34	De Novo Macrocyclic Peptide Inhibitors of Hepatitis B Virus Cellular Entry. Cell Chemical Biology, 2018, 25, 906-915.e5.	2.5	54
35	Expression of a functional intrabody against hepatitis C virus core protein in Escherichia coli and silkworm pupae. Protein Expression and Purification, 2018, 150, 61-66.	0.6	0
36	Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus. PLoS Pathogens, 2018, 14, e1007124.	2.1	78

#	Article	IF	CITATIONS
37	IL- $1\hat{l}^2$ /ATF3-mediated induction of Ski2 expression enhances hepatitis B virus x mRNA degradation. Biochemical and Biophysical Research Communications, 2018, 503, 1854-1860.	1.0	13
38	Rosmarinic acid is a novel inhibitor for Hepatitis B virus replication targeting viral epsilon RNA-polymerase interaction. PLoS ONE, 2018, 13, e0197664.	1.1	40
39	Inhibitory effect of fasiglifam on hepatitis B virus infections through suppression of the sodium taurocholate cotransporting polypeptide. Biochemical and Biophysical Research Communications, 2018, 501, 820-825.	1.0	9
40	A new strategy to identify hepatitis B virus entry inhibitors by AlphaScreen technology targeting the envelope-receptor interaction. Biochemical and Biophysical Research Communications, 2018, 501, 374-379.	1.0	28
41	Recapitulation of hepatitis B virus–host interactions in liver organoids from human induced pluripotent stem cells. EBioMedicine, 2018, 35, 114-123.	2.7	135
42	Troglitazone Impedes the Oligomerization of Sodium Taurocholate Cotransporting Polypeptide and Entry of Hepatitis B Virus Into Hepatocytes. Frontiers in Microbiology, 2018, 9, 3257.	1.5	38
43	Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. Journal of Hepatology, 2017, 66, 685-692.	1.8	99
44	Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection. Scientific Reports, 2017, 7, 45698.	1.6	45
45	Establishment of a human hepatocellular cell line capable of maintaining long-term replication of hepatitis B virus. International Immunology, 2017, 29, 109-120.	1.8	5
46	Amino Acid Mutations in the NS4A Region of Hepatitis C Virus Contribute to Viral Replication and Infectious Virus Production. Journal of Virology, 2017, 91, .	1.5	5
47	Involvement of PUF60 in Transcriptional and Post-transcriptional Regulation of Hepatitis B Virus Pregenomic RNA Expression. Scientific Reports, 2017, 7, 12874.	1.6	22
48	Functional association of cellular microtubules with viral capsid assembly supports efficient hepatitis B virus replication. Scientific Reports, 2017, 7, 10620.	1.6	41
49	A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins. Hepatology, 2017, 65, 1104-1116.	3.6	63
50	Host factor PRPF31 is involved in cccDNA production in HBV-replicating cells. Biochemical and Biophysical Research Communications, 2017, 482, 638-644.	1.0	12
51	Hepatitis B virus prevents excessive viral production via reduction of cell death-inducing DFF45-like effectors. Journal of General Virology, 2017, 98, 1762-1773.	1.3	10
52	Fungus-Derived Neoechinulin B as a Novel Antagonist of Liver X Receptor, Identified by Chemical Genetics Using a Hepatitis C Virus Cell Culture System. Journal of Virology, 2016, 90, 9058-9074.	1.5	27
53	Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus. Scientific Reports, 2016, 6, 28688.	1.6	7
54	Inhibition of preS1-hepatocyte interaction by an array of recombinant human antibodies from naturally recovered individuals. Scientific Reports, 2016, 6, 21240.	1.6	18

#	Article	IF	CITATIONS
55	Human induced pluripotent stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus. Scientific Reports, 2016, 6, 29358.	1.6	42
56	RNA Exosome Complex Regulates Stability of the Hepatitis B Virus X-mRNA Transcript in a Non-stop-mediated (NSD) RNA Quality Control Mechanism. Journal of Biological Chemistry, 2016, 291, 15958-15974.	1.6	23
57	Hepatitis C Virus-Induced Degradation of Cell Death-Inducing DFFA-Like Effector B Leads to Hepatic Lipid Dysregulation. Journal of Virology, 2016, 90, 4174-4185.	1.5	4
58	Prolactin Regulatory Element Binding Protein Is Involved in Hepatitis C Virus Replication by Interaction with NS4B. Journal of Virology, 2016, 90, 3093-3111.	1.5	21
59	Single-domain intrabodies against hepatitis C virus core inhibit viral propagation and core-induced NFI®B activation. Journal of General Virology, 2016, 97, 887-892.	1.3	11
60	Cell Culture Systems for Propagation of HCV. , 2016, , 67-80.		1
61	Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide. Scientific Reports, 2015, 5, 17047.	1.6	42
62	Identification of Antiviral Agents Targeting Hepatitis B Virus Promoter from Extracts of Indonesian Marine Organisms by a Novel Cell-Based Screening Assay. Marine Drugs, 2015, 13, 6759-6773.	2.2	17
63	Isolation and Characterization of an Huh.7.5.1-Derived Cell Clone Highly Permissive to Hepatitis C Virus. Japanese Journal of Infectious Diseases, 2015, 68, 81-88.	0.5	29
64	Dysregulation of Retinoic Acid Receptor Diminishes Hepatocyte Permissiveness to Hepatitis B Virus Infection through Modulation of Sodium Taurocholate Cotransporting Polypeptide (NTCP) Expression. Journal of Biological Chemistry, 2015, 290, 5673-5684.	1.6	58
65	Monoclonal Antibodies against Extracellular Domains of Claudin-1 Block Hepatitis C Virus Infection in a Mouse Model. Journal of Virology, 2015, 89, 4866-4879.	1.5	48
66	Novel Robust in Vitro Hepatitis B Virus Infection Model Using Fresh Human Hepatocytes Isolated from Humanized Mice. American Journal of Pathology, 2015, 185, 1275-1285.	1.9	91
67	Seroepidemiological study of hepatitis B virus markers in Japan. Vaccine, 2015, 33, 6037-6042.	1.7	12
68	A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide. Journal of Virology, 2015, 89, 11945-11953.	1.5	79
69	The RNA Sensor RIG-I Dually Functions as an Innate Sensor and Direct Antiviral Factor for Hepatitis B Virus. Immunity, 2015, 42, 123-132.	6.6	353
70	Development of hepatitis C virus genotype 3a cell culture system. Hepatology, 2014, 60, 1838-1850.	3.6	45
71	NTCP and Beyond: Opening the Door to Unveil Hepatitis B Virus Entry. International Journal of Molecular Sciences, 2014, 15, 2892-2905.	1.8	123
72	Amphipathic α-Helices in Apolipoproteins Are Crucial to the Formation of Infectious Hepatitis C Virus Particles. PLoS Pathogens, 2014, 10, e1004534.	2.1	73

#	Article	IF	CITATIONS
73	Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. Biochemical and Biophysical Research Communications, 2014, 443, 808-813.	1.0	267
74	Production of single-round infectious chimeric flaviviruses with DNA-based Japanese encephalitis virus replicon. Journal of General Virology, 2014, 95, 60-65.	1.3	35
75	Formation of covalently closed circular DNA in Hep38.7-Tet cells, a tetracycline inducible hepatitis B virus expression cell line. Biochemical and Biophysical Research Communications, 2014, 452, 315-321.	1.0	80
76	Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology, 2014, 59, 1726-1737.	3.6	226
77	A class II phosphoinositide 3-kinase plays an indispensable role in hepatitis C virus replication. Biochemical and Biophysical Research Communications, 2013, 440, 150-156.	1.0	11
78	Specific inhibition of hepatitis C virus entry into host hepatocytes by fungi-derived sulochrin and its derivatives. Biochemical and Biophysical Research Communications, 2013, 440, 515-520.	1.0	28
79	Replication of Hepatitis C Virus Genotype 3a in Cultured Cells. Gastroenterology, 2013, 144, 56-58.e7.	0.6	45
80	Signal Peptidase Complex Subunit 1 Participates in the Assembly of Hepatitis C Virus through an Interaction with E2 and NS2. PLoS Pathogens, 2013, 9, e1003589.	2.1	47
81	Interleukin-1 and Tumor Necrosis Factor-α Trigger Restriction of Hepatitis B Virus Infection via a Cytidine Deaminase Activation-induced Cytidine Deaminase (AID). Journal of Biological Chemistry, 2013, 288, 31715-31727.	1.6	140
82	Novel Cell Culture-Adapted Genotype 2a Hepatitis C Virus Infectious Clone. Journal of Virology, 2012, 86, 10805-10820.	1.5	41
83	Japanese Reference Panel of Blood Specimens for Evaluation of Hepatitis C Virus RNA and Core Antigen Quantitative Assays. Journal of Clinical Microbiology, 2012, 50, 1943-1949.	1.8	36
84	Trans-complemented hepatitis C virus particles as a versatile tool for study of virus assembly and infection. Virology, 2012, 432, 29-38.	1.1	27
85	Replication and infectivity of a novel genotype 1b hepatitis C virus clone. Microbiology and Immunology, 2012, 56, 308-317.	0.7	22
86	Production and characterization of HCV particles from serum-free culture. Vaccine, 2011, 29, 4821-4828.	1.7	17
87	Hepatitis C Virus Reveals a Novel Early Control in Acute Immune Response. PLoS Pathogens, 2011, 7, e1002289.	2.1	101
88	Production of Infectious Hepatitis C Virus by Using RNA Polymerase I-Mediated Transcription. Journal of Virology, 2010, 84, 5824-5835.	1.5	44
89	RNA Polymerase Activity and Specific RNA Structure Are Required for Efficient HCV Replication in Cultured Cells. PLoS Pathogens, 2010, 6, e1000885.	2.1	47
90	Biological properties of purified recombinant HCV particles with an epitope-tagged envelope. Biochemical and Biophysical Research Communications, 2010, 395, 565-571.	1.0	9

#	Article	IF	CITATIONS
91	Hepatitis C Virus Controls Interferon Production through PKR Activation. PLoS ONE, 2010, 5, e10575.	1.1	103
92	Evaluation of Hepatitis C Virus Core Antigen Assays in Detecting Recombinant Viral Antigens of Various Genotypes. Journal of Clinical Microbiology, 2009, 47, 4141-4143.	1.8	11
93	Isolation of JFH-1 Strain and Development of an HCV Infection System. Methods in Molecular Biology, 2009, 510, 305-327.	0.4	28
94	Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation. Hepatology, 2008, 48, 732-740.	3.6	56
95	Development of plaque assays for hepatitis C virus-JFH1 strain and isolation of mutants with enhanced cytopathogenicity and replication capacity. Virology, 2008, 371, 71-85.	1.1	37
96	Intragenotypic JFH1 based recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell death. Virology, 2008, 376, 397-407.	1,1	52
97	Trans-encapsidation of hepatitis C virus subgenomic replicon RNA with viral structure proteins. Biochemical and Biophysical Research Communications, 2008, 371, 446-450.	1.0	24
98	Characterization of infectious hepatitis C virus from liver-derived cell lines. Biochemical and Biophysical Research Communications, 2008, 377, 747-751.	1.0	9
99	Interaction of Hepatitis C Virus Nonstructural Protein 5A with Core Protein Is Critical for the Production of Infectious Virus Particles. Journal of Virology, 2008, 82, 7964-7976.	1.5	322
100	Critical Role of Virion-Associated Cholesterol and Sphingolipid in Hepatitis C Virus Infection. Journal of Virology, 2008, 82, 5715-5724.	1.5	186
101	E6AP Ubiquitin Ligase Mediates Ubiquitylation and Degradation of Hepatitis C Virus Core Protein. Journal of Virology, 2007, 81, 1174-1185.	1.5	108
102	The NS3 Helicase and NS5B-to-3′X Regions Are Important for Efficient Hepatitis C Virus Strain JFH-1 Replication in Huh7 Cells. Journal of Virology, 2007, 81, 8030-8040.	1.5	59
103	Production of Infectious Hepatitis C Virus of Various Genotypes in Cell Cultures. Journal of Virology, 2007, 81, 4405-4411.	1.5	95
104	CD81 Expression Is Important for the Permissiveness of Huh7 Cell Clones for Heterogeneous Hepatitis C Virus Infection. Journal of Virology, 2007, 81, 5036-5045.	1.5	112
105	An infectious and selectable full-length replicon system with hepatitis C virus JFH-1 strain. Hepatology Research, 2007, 37, 433-443.	1.8	22
106	The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles. Journal of Medical Virology, 2007, 79, 714-723.	2.5	60
107	The lipid droplet is an important organelle for hepatitis C virus production. Nature Cell Biology, 2007, 9, 1089-1097.	4.6	1,083
108	HCV research and anti-HCV drug discovery: Toward the next generation. Advanced Drug Delivery Reviews, 2007, 59, 1196-1199.	6.6	6

#	Article	IF	CITATIONS
109	Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. Journal of General Virology, 2007, 88, 2495-2503.	1.3	133
110	Replication of a hepatitis C virus replicon clone in mouse cells. Virology Journal, 2006, 3, 89.	1.4	85
111	Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2310-2315.	3.3	338
112	Cell culture and infection system for hepatitis C virus. Nature Protocols, 2006, 1, 2334-2339.	5.5	166
113	Generation of Infectious Hepatitis C Virus in Immortalized Human Hepatocytes. Journal of Virology, 2006, 80, 4633-4639.	1.5	84
114	Hepatitis C Virus Entry Depends on Clathrin-Mediated Endocytosis. Journal of Virology, 2006, 80, 6964-6972.	1.5	480
115	Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Medicine, 2005, 11, 791-796.	15.2	2,561
116	Detection of Anti-Hepatitis C Virus Effects of Interferon and Ribavirin by a Sensitive Replicon System. Journal of Clinical Microbiology, 2005, 43, 5679-5684.	1.8	93
117	Characterization of the E-138 (Glu/Lys) mutation in Japanese encephalitis virus by using a stable, full-length, infectious cDNA clone. Journal of General Virology, 2005, 86, 2209-2220.	1.3	79
118	Robust Production of Infectious Hepatitis C Virus (HCV) from Stably HCV cDNA-Transfected Human Hepatoma Cells. Journal of Virology, 2005, 79, 13963-13973.	1.5	144
119	Robust hepatitis C virus infection in vitro. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9294-9299.	3.3	1,597
120	Nonhepatic Cell Lines HeLa and 293 Support Efficient Replication of the Hepatitis C Virus Genotype 2a Subgenomic Replicon. Journal of Virology, 2005, 79, 592-596.	1.5	115
121	Genotype 2a Hepatitis C Virus Subgenomic Replicon Can Replicate in HepG2 and IMY-N9 Cells. Journal of Biological Chemistry, 2004, 279, 22371-22376.	1.6	105
122	Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology, 2003, 125, 1808-1817.	0.6	536
123	Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. Journal of Medical Virology, 2001, 64, 334-339.	2.5	224